Zubotamig

Genmab binned three antibody programmes as part of a pipeline reprioritisation disclosed during the biotech's quarterly earnings call on Wednesday. The culled assets include GEN1047, a CD3/B7H4 bispecific that was in Phase I/II testing for solid tumours; GEN3017, a CD3/CD30 bispecific that had been in a Phase I study for relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma; and GEN1056, a Phase I antibody that was being evaluated for solid tumours in partnership with BioNTech. "These programs simply didn't meet the high bar we have set internally for really having a truly differentiated therapeutic candidate," CEO Jan Van De Winkel said on the call. "We actually intend to focus more on the winners, and expand the breadth of the winners in the future."The company also said it will no longer launch a Phase III trial of Tivdak (tisotumab vedotin) in second and third line squamous cell carcinoma of the head and neck. The antibody-drug conjugate (ADC) won full FDA approval for cervical cancer in April."We continuously evaluate our clinical pipeline to ensure we are prioritising our resources in the best and most effective way possible," Van De Winkel explained. The pruned pipeline "means we are very focussed on maximising the potential of our Phase III programmes," he added, listing cancer assets Tepkinly/Epkinly (epcoritamab), rinatabart sesutecan (Rina-S), and.The former is in five late-stage studies for various cancers, while acasunlimab, a bispecific directed against PD-L1 and 4-1BB, is expected to enter Phase III by year-end for solid tumours. Rina-S is an ADC that targets folate receptor alpha (FRα) and is in development for tumours that express the protein, with a Phase III trial slated to start this quarter. Autoimmunity up next?Despite the slimdown, Van De Winkel assured investors that they "will again see new programmes added to the pipeline."He pointed to the $1.8-billion buyout of ProfoundBio as another source of candidates; Genmab gained Rina-S via the acquisition, along with two other clinical assets. Van De Winkel also commented that, while mainly oncology-focussed now, the biotech has "a very active number of programmes in preclinical development for autoimmune indications… but they are not yet ready for clinical introduction.""The majority of the work at Genmab over the coming years will still be in cancer, where we have our dominant focus, but we are clearly very interested in exploring innovative ways to move towards autoimmune with the T-cell engager programmes, potentially ADCs, and all our next-generation antibody technologies," he said.